🎉 On the heels of our groundbreaking publication of our Up-LIFT pivotal trial results in nature Medicine last week, Drs. Edelle Field-Fote of Shepherd Center and Candy Tefertiller of Craig, our Up-LIFT and LIFT Home study investigators, presented results from these

🛎️ We are looking forward to sharing more details about our Up-LIFT pivotal trial results, which were published in nature Medicine this week.

On Thursday, May 23rd at 2:30pm CET/8:30am ET following a brief Q1 Business Update, CEO Dave Marver will host a discussion of Up-LIFT

🎉 Today, the results from our Up-LIFT pivotal trial were published in Nature Medicine, one of the world’s preeminent scientific journals.

This Nature Portfolio publication is a key milestone advancing our mission to address the unmet needs of the spinal cord injury (SCI)

Nous sommes impatients de vous voir à VivaTech à Paris, le plus grand événement de startups et de technologie en Europe. VivaTech accélère l'innovation en connectant les startups, les leaders technologiques, les grandes entreprises et les investisseurs qui répondent aux plus

🌟At ONWARD Medical, we’re not just about innovation -- we're about impact. Every important moment and every breakthrough on our journey as a company have been fueled by the stories of strength, perseverance, and hope for progress in the spinal cord injury community.

📹 This is

“Every step you make brings you closer to your dreams.”

We recently had the pleasure of welcoming Belgian keynote speaker Marc Herremans in our Lausanne office. His visit touched us and Marc deeply, as it ignited his own dream “To Walk Again.” For more than 20 years since his own

🎉Congratulations to our research partners and NeuroRestore.swiss co-directors, G Courtine and Bloch Jocelyne , for being named to 2024 TIME100 Health, TIME’s inaugural list of the 100 most influential people in global health this year.🎉

TIME honored the pair for their

✨ Our trial participants are trailblazers. Many signed up for our studies involving ARC Therapy™ to support innovation for the spinal cord injury (SCI) community.

Jessie Owen is one of those trailblazers. She had been injured for 5 years when she found a study evaluating

Thanks to the Institute for Engineering in Medicine and MnDRIVE Brain Conditions for organizing the 11th Annual Minnesota Neuromodulation Symposium last week!

This year, the Neuromodulation Symposium joined forces with the Neuromodulation for Spinal Cord Injury Conference. Our team was therefore eager to

Thank you, Needham & Company, for the opportunity to share our story with the executives, leaders, and investors who attended the 23rd Annual Needham Virtual Healthcare Conference.

Our CEO, Dave Marver, gave a presentation on progress towards our 2024 strategic objectives. Our

🔔 Today is World Parkinson’s Day, which is an opportunity to raise awareness about Parkinson’s disease (PD), a complex, progressive disease that affects the nervous system. We honor those who struggle with the disease and their caregivers. We also salute those working to advance

✨Principal investigators (PIs) are essential to our clinical work. They lead the clinical research team at a study site and execute the clinical trial to the highest standards.

The Up-LIFT global pivotal study involved 14 PIs at leading spinal cord injury (SCI) research centers

Thanks to Sean Whooley of MassDevice for covering our recent De Novo application to the US Food and Drug Administration (FDA) for our investigational ARC-EX® System.

Once cleared by the FDA, ARC-EX will be the first-ever spinal cord stimulation therapy to restore hand and

📣 We are pleased to announce that Stifel has initiated research coverage of our company with a Buy rating and Target Price of EUR 12.00, a premium of 140% to yesterday’s closing price.

Stifel is a US-based full-service investment bank and the largest provider of global

🎉 We have submitted a De Novo medical device application to the US Food & Drug Administration (FDA) for our first-of-its-kind ARC-EX® System designed to restore upper limb function after spinal cord injury (SCI).

The ARC-EX System involves:

⭐️ Targeted electrical stimulation

We ended an important week for ONWARD Medical® by reconnecting with Belgian investors at Saturday’s annual VFB Happening, organized by the VFB vzw.  

Since our IPO on Euronext Brussels in 2021, we have prioritized sharing frequent and transparent updates with the retail

📹 🇫🇷 Our research partners, G Courtine, and Bloch Jocelyne, stopped by BFM Business in Paris, France last week to chat with Laure Closier and Jakubyszyn Christoph on “Good Morning Business” about our plans to commercialize our first product, the investigational ARC-EX® System, in the US

Nos cofondateurs et partenaires de recherche, G Courtine et Bloch Jocelyne, sont à Paris, en France, pour le 'Prix des Personnalités' organisé par l'hebdomadaire français L'Express. 🇫🇷

Nous sommes reconnaissants à L'Express de mettre en lumière le travail important que nos